RGTI
Rigetti Computing
-- 15.7413 LAES
SEALSQ Corp
-- 8.061 TSLA
Tesla
-- 432.881 NVDA
NVIDIA
-- 135.330 KULR
KULR Technology
-- 4.5701 
NEWS
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid).
The analysis showed patients with Peripheral Artery Disease (PAD) taking bempedoic acid were 36% less likely to experience major adverse limb events compared to placebo. Additional data revealed that after 3 months, 67% of patients using bempedoic acid and ezetimibe combination achieved LDL-C levels below 100 mg/dL, with 55% maintaining these levels at 12 months.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
UnluckyDog : Thanks for sharing, sir
DazzlerAus : This thing is so undervalued